Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Back
Association details:
Biomarker:
HLA-DQB1*03:01
Cancer:
Small Cell Lung Cancer
Drug:
Imfinzi (durvalumab)
(
PD-L1 inhibitor
) +
Imjudo (tremelimumab)
(
CTLA4 inhibitor
)
Direction:
Sensitive
Evidence:
Evidence Level:
Sensitive: B - Late Trials
Source:
IASLC-WCLC 2021
Title:
MA16.06 - Durvalumab ± Tremelimumab + Platinum-Etoposide in 1L ES-SCLC: Exploratory Analysis of HLA Genotype and Survival in CASPIAN
Published date:
08/18/2021
Excerpt:
In CASPIAN, the presence of the HLA-DQB1*03:01 allele was associated with improved OS for durvalumab + tremelimumab + EP treatment.
Secondary therapy:
EP
Trial ID:
CASPIAN
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login